Table 4.
Serological status by HPV DNA status at study entry (total vaccinated cohort)
| Total |
||||
|---|---|---|---|---|
|
N = 6,0351 |
||||
| HPV type | HPV DNA status (from cervical sample) | Antibody status | n | % |
| HPV-16 | DNA negative | Seronegative | 4,132 | 68.5 |
| Seropositive | 1,681 | 27.9 | ||
| DNA positive | Seronegative | 62 | 1.0 | |
| Seropositive | 160 | 2.7 | ||
| HPV-18 | DNA negative | Seronegative | 5,027 | 83.3 |
| Seropositive | 932 | 15.4 | ||
| DNA positive | Seronegative | 39 | 0.6 | |
| Seropositive | 35 | 0.6 | ||
| Missing serology | 2 | – | ||
1
Baseline data were not available for 16 participants due to unsatisfactory cervical samples.
N, number of subjects with available results; n, number of subjects in given category; %, n/N × 100.